Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

119.25 +7.79 (+6.99%)
Streaming Delayed Price Updated: 10:18 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
From Moderna, Inc.
Via Business Wire
Moderna Announces Expansion of its Manufacturing Technology Center in Massachusetts
From Moderna, Inc.
Via Business Wire
Moderna Announces Supply Agreement with Gavi for up to 500 Million Doses of COVID-19 Vaccine Moderna for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
From Moderna, Inc.
Via Business Wire
Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022
From Moderna, Inc.
Via Business Wire
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via Business Wire
Moderna Announces New Supply Agreement with Israel for 2022
From Moderna, Inc.
Via Business Wire
Moderna to Report First Quarter Financial Results on Thursday, May 6, 2021
From Moderna, Inc.
Via Business Wire
Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development
From Moderna, Inc.
Via Business Wire
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
From Moderna, Inc.
Via Business Wire
Moderna to Present at the 20th Annual Needham Virtual Healthcare Conference
From Moderna, Inc.
Via Business Wire
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine
From Moderna, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.